Ibrexafungerp: A novel oral glucan synthase inhibitor

Med Mycol. 2020 Jul 1;58(5):579-592. doi: 10.1093/mmy/myz083.

Abstract

Ibrexafungerp is a novel glucan synthase inhibitor currently undergoing phase II and phase III clinical trials. This compound has demonstrated in vitro activity against clinically important fungal pathogens including Candida spp. and Aspergillus spp. It is able to retain activity against many echinocandin-resistant strains of Candida due to differential avidity for the target site compared to echinocandins. In vivo animal models have demonstrated efficacy in murine models of invasive candidiasis, aspergillosis, and pneumocystis. Due to high bioavailability, it can be administered both orally and intravenously. A favorable drug interaction and tolerability profile is observed with this compound. This review summarizes existing data that have either been published or presented at international symposia.

Keywords: antifungal; aspergillosis; candidiasis; in vitro activity; in vivo studies.